Status:
TERMINATED
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.
Conditions:
Methamphetamine Dependence
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Trea...
Detailed Description
This is a Phase II, randomized, double-blind, placebo-controlled, intent-to-treat, 2-arm, parallel design, multicenter study to evaluate vigabatrin as a treatment for methamphetamine addiction. The st...
Eligibility Criteria
Inclusion
- Able to understand the study and provide written informed consent.
- Male or female at least 18 years of age.
- Meets DSM-IV (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) criteria for methamphetamine dependence as major diagnosis, as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV).
- Provides at least one urine specimen which is positive for methamphetamine according to a rapid screening test.
- Seeking treatment for methamphetamine dependence.
- Have normal visual fields.
- Be in generally good health based on history, physical examination and laboratory findings.
- If female of childbearing potential, use acceptable contraceptive methods
Exclusion
- Has current dependence on any psychoactive substance other than methamphetamine, alcohol, nicotine, or cannabinoid or physiologic dependence on alcohol requiring medical detoxification.
- Has any serious medical or psychiatric illness and/or clinically significant abnormal laboratory values.
- Has history of serious cardiovascular reaction to methamphetamine.
- Has clinically significant cardiovascular impairment, abnormal ECG or uncontrolled hypertension.
- Be under court or other governmental agency (e.g. social services) mandate to obtain treatment or requiring outside urine monitoring.
- Be enrolled in an opiate substitution treatment program within 2 months of randomization.
- Has ever taken vigabatrin in the past.
- Is pregnant or lactating.
- Has clinically significant ophthalmologic disease, which would preclude safety monitoring, is undergoing treatment for ocular disease or intends to have any ocular surgery or procedure performed during the time of their participation in the trial.
- Has received a drug with known major organ toxicity, including retinotoxicity.
- Is currently participating in, or has been enrolled in another clinical trial within the last 30 days.
- Be anyone who, in the judgment of the investigator, would not be expected to attend regular study visits or to complete the study protocol.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00730522
Start Date
July 1 2008
End Date
November 1 2009
Last Update
December 9 2020
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
North County Clinical Research (NCCR)
Oceanside, California, United States
2
South Bay Treatment Center
San Diego, California, United States
3
Addiction Pharmacology Research Laboratory, St. Luke's Hospital
San Francisco, California, United States
4
START Research and Treatment
Kansas City, Missouri, United States